Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Erlotinib can cause hair loss as a side effect.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Ritlecitinib can help about 14,000 people with severe hair loss.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

JAK inhibitors can enter the skin through hair follicles using a unique pathway.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Sorafenib can cause rare skin reactions, but treatment can continue with additional care.